Trial Profile
The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions
- Acronyms BK Registry; BRILIANT; BRILIANT KOREA
- 18 Aug 2015 New trial record